Vor Biopharma, Inc. (VOR)

Vor Bio announced a $75 million private placement with TCGX in late March 2026, following a $150 million private placement in mid-December 2025. The company reported its fourth quarter and full year 2025 financial results and provided a corporate update in late March 2026. Vor Bio dosed the first patient in its global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease in late March 2026. In December 2025, JPMorgan initiated coverage with an "Overweight" rating and a $43 price target. A director, Ra Capital Management, LLC, executed a major sale of 620,133 shares of Vor Biopharma stock valued at over $10 million in April 2026. Vor Bio reported inducement grants under Nasdaq Listing Rule 5635(c)(4) in early April and late March 2026. The company participated in the 46th Annual TD Cowen Health Care Conference in February 2026 and the 44th Annual J.P. Morgan Healthcare Conference in January 2026.

Information regarding the direct demand seasonality for Vor Biopharma's products and services is not explicitly available. Based on historical stock price data, December has the highest probability of positive returns at 100%, while April has a 0% probability of positive returns.

Vor Biopharma, Inc. is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases through the development of telitacicept, a novel dual-target fusion protein. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). Vor Biopharma is also advancing telitacicept through global Phase 3 clinical development for serious autoantibody-driven conditions worldwide. In addition to its focus on autoimmune diseases, Vor Biopharma is also described as a clinical-stage cell therapy company that combines a novel patient engineering approach with targeted therapies for patients with hematological malignancies.

Vor Biopharma Inc. is headquartered in Boston, Massachusetts, with another office in Cambridge, Massachusetts, United States. While telitacicept is approved in China for several indications, the company is actively pursuing global development. A global Phase 3 clinical trial for generalized myasthenia gravis (gMG) is underway across the United States, Europe, and South America to support potential approvals in these regions.

Over the past year, Vor Biopharma's brand reputation, as reflected by analyst sentiment, has generally been positive, with a consensus rating of "Moderate Buy" from 13 Wall Street analysts. However, an AI analyst from TipRanks gives VOR a "Neutral" rating, primarily due to weak financial performance. Another AI model from Danelfin gives Vor Biopharma Inc. a "Strong Sell" rating with a 40% probability of outperforming the market in the next three months. Events that have affected the company's reputation in the past year include its strategic pivot to autoimmune diseases via the telitacicept license and raising over $500 million in 2025 to advance telitacicept for U.S. approval.

Vor Biopharma Inc. has a significant institutional ownership, with 64 institutional owners and shareholders holding a total of 25,530,162 shares. Institutional ownership accounts for approximately 99.58% of shares, while individuals hold about 3.3%. VC/PE firms hold 27.1% and individual insiders hold 2.19%. Major institutional owners include RA Capital Management, L.P., Fcpm Iii Services B.v., Frazier Life Sciences Management, L.P., Fmr Llc, VR Adviser, LLC, Paradigm Biocapital Advisors LP, Great Point Partners Llc, NEXTBio Capital Management LP, Susquehanna International Group, Llp, Caligan Partners LP, The Vanguard Group, Inc., BlackRock, Inc., and The Goldman Sachs Group, Inc.